ReviewLangenbeck's archives of surgery2008
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.
Review in Langenbeck's archives of surgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).Cancer chemotherapy and pharmacology · 2014Trial
- Alteration in the expression of the chemotherapy resistance‑related genes in response to chronic and acute hypoxia in pancreatic cancer.Biomedical reports · 2023Article
- Pancreatic Cancer: Beyond Brca Mutations.Journal of personalized medicine · 2022Review
- Platelet-Vesicles-Encapsulated RSL-3 Enable Anti-Angiogenesis and Induce Ferroptosis to Inhibit Pancreatic Cancer Progress.Frontiers in endocrinology · 2022Article
- NOX4: a potential therapeutic target for pancreatic cancer and its mechanism.Journal of translational medicine · 2021Review
- IL10-modified Human Mesenchymal Stem Cells inhibit Pancreatic Cancer growth through Angiogenesis Inhibition.Journal of Cancer · 2020Article
- Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer.The Journal of pharmacology and experimental therapeutics · 2019Review
- Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.Nature communications · 2017Article
- Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.Cancer letters · 2016Review
- Targeting tumor-associated macrophages to combat pancreatic cancer.Oncotarget · 2016Review
- Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.World journal of gastroenterology · 2016Review
- Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.World journal of gastroenterology · 2016Review
- Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.Oncotarget · 2015Article
- Pancreatic cancer stroma: friend or foe?Cancer cell · 2014Article
- Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization.Scientific reports · 2014Article
- Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.British journal of cancer · 2014Article
- Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability.Oncogene · 2013Article
- Tumor-stromal interactions in pancreatic cancer.Critical reviews in oncogenesis · 2013Review
- Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.Langenbeck's archives of surgery · 2012Review
- Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.Cancer research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20% of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival. MATERIALS AND
methodsThis review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.